Great West Life Assurance Co. Can increased its position in shares of bluebird bio, Inc. (NASDAQ:BLUE) by 22.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,531 shares of the biotechnology company’s stock after acquiring an additional 1,022 shares during the period. Great West Life Assurance Co. Can’s holdings in bluebird bio were worth $778,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. QS Investors LLC increased its holdings in bluebird bio by 70.7% during the 2nd quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock worth $127,000 after purchasing an additional 500 shares during the period. Biondo Investment Advisors LLC purchased a new stake in bluebird bio during the 3rd quarter worth about $203,000. World Asset Management Inc purchased a new stake in bluebird bio during the 3rd quarter worth about $230,000. Bank of Montreal Can increased its holdings in bluebird bio by 118.9% during the 2nd quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock worth $176,000 after purchasing an additional 911 shares during the period. Finally, Comerica Bank purchased a new stake in bluebird bio during the 3rd quarter worth about $242,000.
Several brokerages have weighed in on BLUE. CIBC began coverage on bluebird bio in a report on Thursday. They set a “market perform” rating on the stock. Oppenheimer began coverage on bluebird bio in a report on Wednesday, December 20th. They set a “market perform” rating on the stock. Leerink Swann restated an “outperform” rating and set a $120.00 price target on shares of bluebird bio in a report on Saturday, September 30th. SunTrust Banks upped their price target on bluebird bio to $223.00 and gave the stock a “buy” rating in a report on Tuesday, December 12th. Finally, Wells Fargo & Co restated an “outperform” rating and set a $242.00 price target (up previously from $190.00) on shares of bluebird bio in a report on Tuesday, December 12th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and thirteen have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $157.45.
bluebird bio (NASDAQ:BLUE) last released its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($1.73) EPS for the quarter, missing analysts’ consensus estimates of ($1.68) by ($0.05). bluebird bio had a negative net margin of 883.18% and a negative return on equity of 28.79%. The business had revenue of $7.71 million during the quarter, compared to analysts’ expectations of $8.47 million. During the same quarter in the previous year, the company posted ($2.07) EPS. The company’s revenue was up 397.4% compared to the same quarter last year. analysts expect that bluebird bio, Inc. will post -6.7 earnings per share for the current year.
In related news, insider Jeffrey T. Walsh sold 4,900 shares of the company’s stock in a transaction dated Tuesday, October 10th. The stock was sold at an average price of $129.94, for a total value of $636,706.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Nick Leschly sold 117,500 shares of the company’s stock in a transaction dated Wednesday, December 13th. The shares were sold at an average price of $184.08, for a total value of $21,629,400.00. Following the completion of the sale, the insider now directly owns 293,232 shares of the company’s stock, valued at $53,978,146.56. The disclosure for this sale can be found here. In the last quarter, insiders sold 215,082 shares of company stock worth $37,227,332. Company insiders own 3.90% of the company’s stock.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio, Inc. (NASDAQ:BLUE).
What are top analysts saying about bluebird bio? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for bluebird bio and related companies.